Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway

Hepatology

Volumn 53, Issue 3, 2011, Pages 843-853

  Liu, Weili ^a,b   Li, Xiaoxing ^a   Chu, Eagle S H ^a   Go, Minnie Y Y ^a   Xu, Lixia ^a   Zhao, Guijun ^c   Li, Lili ^a   Dai, Ning ^b   Si, Jianmin ^b   Tao, Qian ^a   Sung, Joseph J Y ^a   Yu, Jun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ZHEJIANG UNIVERSITY   (China)

^c INNER MONGOLIA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FAS LIGAND; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN ALPHA; LEUCINE RICH REPEAT; LUCIFERASE; POLY(RC)BINDING PROTEIN 4; PROTEIN; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BISULFITE GENOMIC SEQUENCING; CANCER INHIBITION; CARCINOGENICITY; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOSS; GENE SILENCING; GENETIC PROCEDURES; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIRED BOX GENE 5; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 79952208276     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24124     Document Type: Article

References (49)

1. Mohammad HS. Hepatocellular carcinoma. Hepat Month 2005; 5: 65-76.
2. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
3. Schafer BW. Emerging roles for PAX transcription factors in cancer biology. Gen Physiol Biophys 1998; 17: 211-224.
4. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992; 12: 2662-2672.
5. Holmes ML, Pridans C, Nutt SL. The regulation of the B-cell gene expression programme by Pax5. Immunol Cell Biol 2008; 86: 47-53.
6. Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity 2007; 26: 715-725.
7. Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 1994; 79: 901-912.
8. Palmisano WA, Crume KP, Grimes MJ, Winters SA, Toyota M, Esteller M, et al. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 2003; 63: 4620-4625.
9. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007; 73: 1-14.
10. Stuart ET, Kioussi C, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1995; 1: 207-214.
11. Steinbach JP, Kozmik Z, Pfeffer P, Aguzzi A. Overexpression of Pax5 is not sufficient for neoplastic transformation of mouse neuroectoderm. Int J Cancer 2001; 93: 459-467.
12. Vidal LJ, Perry JK, Vouyovitch CM, Pandey V, Brunet-Dunand SE, Mertani HC, et al. PAX5alpha enhances the epithelial behavior of human mammary carcinoma cells. Mol Cancer Res 2010; 8: 444-456.
13. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002; 11: 2091-2102.
14. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009; 136: 640-651 e641.
15. Yu J, Shen B, Chu ES, Teoh N, Cheung KF, Wu CW, et al. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. HEPATOLOGY 2010; 51: 2008-2019.
16. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191.
17. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 1998; 17: 4905-4908.
18. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
19. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007; 449: 473-477.
20. Gaspar N, Grill J, Geoerger B, Lellouch-Tubiana A, Michalowski MB, Vassal G. p53 Pathway dysfunction in primary childhood ependymomas. Pediatr Blood Cancer 2006; 46: 604-613.
21. Babjuk M, Soukup V, Mares J, Duskova J, Sedlacek Z, Trkova M, et al. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol 2002; 34: 495-501.
22. Tang X, Molina M, Amar S. p53 short peptide (p53pep164) regulates lipopolysaccharide-induced tumor necrosis factor-alpha factor/cytokine expression. Cancer Res 2007; 67: 1308-1316.
23. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
24. Donato NJ, Perez M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J Biol Chem 1998; 273: 5067-5072.
25. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
26. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000; 14: 1509-1513.
27. Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet 2000; 26: 122-127.
28. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 371-86.
29. Borrelli S, Candi E, Alotto D, Castagnoli C, Melino G, Viganò MA, et al. p63 regulates the caspase-8-FLIP apoptotic pathway in epidermis. Cell Death Differ 2009; 16: 253-63.
30. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
31. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
32. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
33. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
34. Zhu J, Chen X. MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M. Mol Cell Biol 2000; 20: 5602-5618.
35. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 2000; 275: 22627-22630.
36. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
37. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, et al. Genomic instability in Gadd45a-deficient mice. Nat Genet 1999; 23: 176-184.
38. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A 1999; 96: 3706-3711.
39. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843-846.
40. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113(Pt 10): 1661-1670.
41. Sang HS, Dong YS, Su HH, Sang EP, Yung HC, Sang HH. Euphorbiae humifusae induces apoptosis in Hep3B hepatocarcinoma cells via simultaneous activation of the death receptor-mediated and mitochondrial pathways. Int J Mol Med 2009; 2: 221-227.
42. Kim JS, Lee JM, Chwae YJ, Kim YH, Lee JH, Kim K, et al. Cisplatin-induced apoptosis in Hep3B cells: mitochondria-dependent and -independent pathways. Biochem Pharmacol 2004; 67: 1459-1468.
43. Kaelin WG Jr. The emerging p53 gene family. J Natl Cancer Inst 1999; 91: 594-598.
44. Tozluoglu M, Karaca E, Haliloglu T, Nussinov R. Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res 2008; 36: 5033-5049.
45. Stiewe T, Putzer BM. p73 in apoptosis. Apoptosis 2001; 6: 447-452.
46. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004; 279: 8076-8083.
47. Martin AG, Trama J, Crighton D, Ryan KM, Fearnhead HO. Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B. Aging (Albany NY) 2009; 1: 335-349.
48. Wang P, Yu W, Hu Z, Jia L, Iyer VR, Sanders BG, et al. Involvement of JNK/p73/NOXA in vitamin E analog-induced apoptosis of human breast cancer cells. Mol Carcinog 2008; 47: 436-45.
49. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008; 68: 8998-9004.